Cart
sales@molnova.com
TFMB-(R)-2-HG
CAS No. 1445700-01-5
TFMB-(R)-2-HG( —— )
Catalog No. M23608 CAS No. 1445700-01-5
TFMB-(R)-2-HG is a carcinogenic factor in Acute myeloid leukemia (AML). TFMB-(R)-2-HG impairs SCF ER-Hoxb8 cell differentiation in response to estrogen withdrawal.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 88 | In Stock |
|
| 5MG | 152 | In Stock |
|
| 10MG | 237 | In Stock |
|
| 25MG | 441 | In Stock |
|
| 50MG | 651 | In Stock |
|
| 100MG | 888 | In Stock |
|
| 500MG | 1782 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTFMB-(R)-2-HG
-
NoteResearch use only, not for human use.
-
Brief DescriptionTFMB-(R)-2-HG is a carcinogenic factor in Acute myeloid leukemia (AML). TFMB-(R)-2-HG impairs SCF ER-Hoxb8 cell differentiation in response to estrogen withdrawal.
-
DescriptionTFMB-(R)-2-HG is a carcinogenic factor in Acute myeloid leukemia (AML). TFMB-(R)-2-HG impairs SCF ER-Hoxb8 cell differentiation in response to estrogen withdrawal.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorCarcinogenic factor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1445700-01-5
-
Formula Weight288.22
-
Molecular FormulaC13H11F3O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:240 mg/mL (832.7 mM)
-
SMILESO=C([C@@H](CC1)OC1=O)OCC2=CC=CC(C(F)(F)F)=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Losman JA, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013 Mar 29;339(6127):1621-5.
molnova catalog
related products
-
SPACE peptide
SPACE peptide is a skin penetrating peptide that facilitates the transfer of molecules through the skin.
-
PAR-2 (6-1) amide (h...
PAR-2 (6-1) amide (human)
-
Miriplatin hydrate
Miriplatin hydrate (SM-11355 (hydrate)) (MPT) is a novel platinum complex used in TACE that shows promise for the treatment of hepatocellular carcinoma (HCC).
